ViroGates A/S announced that the distribution partner in Germany bestbion dx GmbH has started successful selling suPARnostic® for clinical use, to guide anakinra treatment in adult COVID-19 patients, in several hospitals in the German market. ViroGates are supplying products to bestbion dx on a centralized basis and cannot inform of details of the individual accounts.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.9 DKK | 0.00% | -1.15% | +14.62% |
1st Jan change | Capi. | |
---|---|---|
+14.62% | 6.47M | |
-32.63% | 9.2B | |
-5.66% | 3.12B | |
+23.12% | 2.8B | |
-18.33% | 2.05B | |
-24.39% | 1.59B | |
+65.65% | 1.44B | |
+32.83% | 830M | |
-6.77% | 720M | |
-29.80% | 507M |
- Stock Market
- Equities
- VIRO Stock
- News ViroGates A/S
- ViroGates A/S Announces bestbion dx GmbH as Distribution Partner in Germany